Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: ImmunityBio is a vertically-integrated commercial-stage biotechnology company focused on immunotherapies. Its primary approved product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an IL-15 receptor superagonist approved by the FDA (April 2024) and MHRA (July 2025) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The company is also developing a pipeline of cytokine fusion proteins, vaccine vectors, and cell therapies.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $32,061 | $6,106 | $75,003 | $7,193 |
| Net Loss (Attributable to Common Stockholders) | $(67,253) | $(85,729) | $(289,454) | $(354,402) |
| Net Loss Per Share (Diluted) | $(0.07) | $(0.14) | $(0.32) | $(0.53) |
| Cash and Cash Equivalents | $60,241 | $143,428 | $60,241 | $143,428 |
| Marketable Securities | $197,572 | $6,381 | $197,572 | $6,381 |
| Total Liquidity (Cash + Securities) | $257,813 | $149,809 | $257,813 | $149,809 |
| Related-Party Convertible Note (Fair Value) | $500,804 | $461,877 | $500,804 | $461,877 |
| Revenue Interest Liability | $316,145 | $284,404 | $316,145 | $284,404 |
| Warrant Liabilities | $115,160 | $8,575 | $115,160 | $8,575 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 425% in Q3 2025 compared to Q3 2024, driven by a 434% increase in product revenue from ANKTIVA sales. Year-to-date revenue increased 943%.
- Loss Reduction: Net loss decreased 22% in Q3 2025 and 18% for the nine months ended September 30, 2025, compared to the prior year periods, despite continued high operating expenses.
- Liquidity Position: Total cash, cash equivalents, and marketable securities increased to $257.8 million as of September 30, 2025, from $149.8 million at year-end 2024, bolstered by equity offerings.
- Liability Volatility: Warrant liabilities increased significantly to $115.2 million (from $8.6 million at year-end 2024) due to the issuance of new warrants in April and July 2025 Registered Direct Offerings (RDOs). The fair value of the related-party convertible note increased to $500.8 million.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 12% year-to-date, primarily due to lower legal expenses and litigation settlements compared to the prior year.
Guidance, Outlook, and Risks
- Commercialization: The company continues to commercialize ANKTIVA in the U.S. and the UK. It received a "Refusal to File" (RTF) letter from the FDA in May 2025 regarding its sBLA for the papillary NMIBC indication, requiring a randomized controlled trial (RCT). Management is evaluating regulatory paths and has a meeting scheduled with the FDA for December 2025.
- Clinical Pipeline: Early results from glioblastoma (GBM) and non-Hodgkin lymphoma (NHL) trials showed promising disease control and complete responses. Enrollment has initiated in a Phase 3 study for non-small cell lung cancer (NSCLC).
- Liquidity and Going Concern: Management states that substantial doubt exists regarding the company's ability to continue as a going concern without additional funding. However, they believe existing cash, product sales, and potential equity offerings (including support from the Founder/Executive Chairman) will fund operations for at least the next 12 months.
- Debt Obligations: The company has significant obligations under the Revenue Interest Purchase Agreement (RIPA) with Oberland, requiring quarterly payments based on net sales. There is also a $505 million related-party convertible note due in 2027.
- Legal Proceedings: A securities class action was settled for $10.5 million in June 2025. Shareholder derivative actions regarding related-party transactions and CMO disclosures were preliminarily approved for settlement in July 2025, pending final court approval in November 2025.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of ANKTIVA sales and the impact of the BCG shortage on market uptake.
- Regulatory Path for Papillary Indication: Monitor the outcome of the December 2025 FDA meeting regarding the RTF letter and the feasibility of the required RCT.
- Cash Burn Rate: Assess the runway provided by the $257.8 million liquidity position against the $234.6 million cash used in operating activities for the first nine months of 2025.
- Debt and Liability Structure: Review the terms of the RIPA and the $505 million related-party note, specifically the conversion features and repayment triggers.
- Legal Settlements: Confirm the final approval and payment terms of the pending shareholder derivative action settlements.
- Dilution Risk: Evaluate the impact of outstanding warrants (65 million shares), options, and Contingent Value Rights (CVRs) on future share count.